Glucagon-like peptide-1 derivatives and dipeptidyl peptidase-IV inhibitors: New hope for the treatment of type-2 diabetes

Saudi Medical Journal

Volumn 26, Issue 10, 2005, Pages 1511-1515

  Al Omar, Mohamed A ^a   Al Arifi, Mohammed N ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ALBUGON; ANTIDIABETIC AGENT; BMS 477188; CJC 1131; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FE 999011; GASTROINTESTINAL HORMONE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GSK 23A; INSULIN; LIRAGLUTIDE; METFORMIN; NVP DDP 728; SERUM ALBUMIN; SITAGLIPTIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ZP 10;

CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PROTEASE INHIBITORS; SENSITIVITY AND SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29144530172     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Bell GI, Santerre RF, Mullenbach GT, Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718.
2. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in human preproglucagon gene. Nature 1983; 304: 368-371.
3. Heinrich G, Gros P, Lund PK, Bently RC, Habener JF, Heinrich G. Preproglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. Endocrinology 1984; 115: 2176-2181.
4. Orskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 1992; 35: 701-711.
5. Kieffer TJ, Habener JL. The glucagon-like peptide. Endocr Rev 1999; 20: 876-913.
6. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine section from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-2013.
7. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1-(7-36)-amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-166.
8. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal (INS-1)-cells. Diabetologia 1999; 42: 856-864.
9. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Egan JM, Bonner-Weir S. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase β-cell mass in mouse pancreas. Diabetes 2000; 49: 741-748.
10. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents β-cell glucolipotoxicity. Diabetologia 2004; 47: 806-815.
11. Wettergren A, Schjoldager I, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
12. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792.
13. Zander M, Madsbad S, Madsent, JL. Effect of 6-weeks course of glucagon-like peptide-1 on glycaemia control, insulin sensitive, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830.
14. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effect of glucagon-like peptide-1 (GLP-1) can directly protect the heart against ischaemia/reperfusion injury. Circulation 2004; 109: 962-965.
15. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increase blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52.
16. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic human. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
17. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135-148.
18. Visboll T, Agerso H, Krarup T, Holst JJ. Similar elimination rates of glucagon-like peptide 1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003; 88: 220-224.
19. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to Glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363.
20. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptdyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41: 271-278.
21. Eng J, Kleinman WA, Singh L, Singh GR, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 2003; 267: 402-405.
22. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patient with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
23. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161.
24. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 2004; 4: 589-596.
25. Dalton LW. Drugs for diabetes: new therapies targeting hormone in the gut promise more benefits than existing drugs and show potential for regenerating beta cells. Chem Eng 2004; 25: 59-65.
26. Ribel U, Larsen MO, Rolin B, Carr RD, Wiken M, Sturis J, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 217-225.
27. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751-759.
28. Bloom M, Bock J, Duttaroy A, Grzegorzewski K, Moor P, Ou Y, et al. Albugon fusion protein: a long acting analogue of GLP-1 that provides lasting antidiabetic effect in animal. Diabetes 2003; 52: A112.
29. Liu HK, Green BD, Gault VA, McCluskey JT, McClenaghan NH, O'Harte FPM, et al. N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic β-cel associated gene expression. Cell Biol Int 2004; 28: 69-73.
30. O'Harte FPM, Mooney MH, Lawlor A, Flatt PR. N-terminally modified glucagon-like peptide-1 (7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochem Biophys Acta 2000; 1474: 13-22.
31. Juhl CR, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429.
32. Madsbad S, Schmitz O, Ransstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
33. Nauck MA, Hompesch M, Filipicazak R, Le TDT, Nielsen LL, Zdravkovic M. Liraglutide significantly improves glycemic control and reduced body weight compared with glimpiride as add-on to metformin in type 2 diabetes. Diabetes 2004; 53: A83.
34. Saad M, An B, Santiago O. The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with type 2 diabetes. Diabetologia 2002; 45: A44.
35. Lawrence B, Dreyfus J, Wen S, Guicarc'h P, Drucker D, Castaigne JP. CJC-1131, a long acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Diabetes 2003; 52: A125.
36. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vivo yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. J Clin Endocrinol 1995; 80: 952-957.
37. Rolin B, Deacon CF, Carr RD, Ahrén B. The major glucagon-like peptide-1 metabolites, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice. Eur J Pharmacol 2004; 494: 283-288.
38. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to beside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Cli Lab Sci 2003; 40: 209-294.
39. Weber AE, Kim D, Beconi M. MK-0431 is a potent, selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Diabetes 2004; 53: A151.
40. Reimer MK, Holst JJ, Ahren B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002; 146: 717-727
41. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduce glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
42. Ahren B, Gomis R, Standl E, Mills D, Schweizer A, editors. A prolonged efficacy of LAF237 in patients with type 2 diabetes (T2DM) inadequately treated with metformin. 64th Scientific Sessions of American Diabetes Association; 2004 June 4-8; Orlando, USA. Orlando: American Diabetes Association; 2004.
43. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CHS, Demuth HU. Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
44. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, et al. A Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 52: 943-950.
45. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, et al. Chronic inhibition circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes 2002; 51: 1461-1469.
46. Herman GA, Zhao PL, Dietrich E. The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. Diabetes 2004; 53: A82.
47. Heins J, Glund K, Hoffmann T, Metzner J, Demuth HU. The DP-IV inhibitor P93/01 improves glucose tolerance in humans with HbA1c greater than 6. Diabetes 2004; 53: A128.